Jan-14 -

Genito-Urinary Group

EORTC 30962 – Comparative study of intravesical BCG standard dose long-term maintenance versus BCG 1/3 dose long-term maintenance versus BCG standard dose short-term maintenance versus BCG 1/3 dose short-term maintenance in intermediate and high risk Ta- T1 Papillary Carcinoma of the Urinary Bladder.

EORTC study showed that in patients with intermediate and high risk Ta- T1 Papillary Carcinoma of the Urinary Bladder, reducing the the dose or duration of the recommended intravesical immunotherapy treatment (Bacillus Calmette-Guérin (BCG)), does not change its side effects for these patients.

READ MORE

Go to Top